Impact of Gene Mutations on Response to Lenalidomide and OS in Lower-Risk Non-Del(5Q) MDS Patients Ineligible/Refractory to Erythropoiesis-Stimulating Agents (ESAS). (April 2017) - Santini, V.; Fenaux, P.; Giagounidis, A.; Platzbecker, U.; Almeida, A.; List, A.F.; Zhong, J.; Wu, C.; Mavrommatis, K.; Beach, C.L.; MacBeth, K.J.